5 Min Read

Psilocybin Shows Promise for Anhedonia in New CU Anschutz Trial

Premier Integrative & Cognitive Medical Institute
A man smiling happily with scenic mountains in the background

Depression is often described as sadness, but for many people one of its hardest symptoms is something quieter: losing the ability to enjoy life. Favorite hobbies feel flat, time with loved ones feels empty, and the things that once brought joy no longer do. This symptom is called anhedonia, and it affects an estimated 82–92% of people with major depression.

Anhedonia is also notoriously hard to treat. It's linked to treatment-resistant depression and lower quality of life, and it often lingers even after other symptoms improve. In one study of people whose depression had otherwise gone into remission on an antidepressant, more than a quarter still reported anhedonia.

A new study from the University of Colorado Anschutz Medical Campus, published in the Journal of Affective Disorders, offers encouraging news. Researchers found that psilocybin-assisted therapy was linked to improvements in anhedonia and significant reductions in depression in people with treatment-resistant depression. Notably, participants were able to stay on their regular antidepressants throughout the study.

How the Study Worked

The trial was a randomized, double-blind, placebo-controlled pilot study, the kind of design researchers use to compare treatments fairly:

  • Participants: 20 adults with treatment-resistant major depression, meaning other treatments hadn't given them enough relief.
  • Two doses: 11 participants received a full 25 mg dose of psilocybin, and 9 received a 1 mg dose that served as the placebo comparison. Neither participants nor researchers knew who received which.
  • Psychological support: Both groups received psilocybin alongside psychological support, the standard approach in psilocybin-assisted therapy.
  • Antidepressants allowed: Participants could keep taking antidepressants such as SSRIs and SNRIs, unlike most psilocybin trials, which require people to stop them first.
  • Thorough follow-up: Researchers measured anhedonia with two different scales, plus overall depression, at one week and eight weeks. Every participant completed every follow-up visit.

Key Findings: Encouraging Results for Anhedonia and Depression

The results were promising across several measures. People who received 25 mg of psilocybin showed significantly greater improvement in anhedonia than the comparison group on one measure at one week, and on the other measure at eight weeks. While the study's main one-week measure narrowly missed statistical significance, the overall pattern points toward real benefits for people's ability to feel interest, motivation, and pleasure.

The improvements in overall depression were even clearer. Depression scores dropped significantly more in the 25 mg group, and the difference was just as strong at eight weeks as it was at one week. That suggests the benefits of a single treatment held steady for at least two months.

The fact that participants stayed on their antidepressants matters too. Stopping antidepressants before psilocybin therapy can be a long, difficult process, and symptoms can worsen in the meantime. This study adds to early evidence that psilocybin therapy may be possible without that step, which could make it a more realistic option for many people.

Why Might Psilocybin Help With Anhedonia?

Anhedonia is closely tied to the brain's reward system, which helps us feel motivated and enjoy rewarding experiences. Research suggests psilocybin may act directly on this system. It activates serotonin receptors that trigger increases in dopamine, a key chemical messenger for motivation and pleasure. Brain imaging research has also found changes in connections between reward-related brain regions in the weeks after psilocybin treatment, which may help explain longer-lasting effects. Animal studies support this too: psilocybin has been shown to restore motivated behavior after chronic stress.

What This Means for People With Treatment-Resistant Depression

This was a pilot study, and the researchers note that larger trials are needed to confirm the results. Even so, it marks an important step forward. It's one of the first controlled trials to look specifically at psilocybin and anhedonia, and its findings add to a growing body of research on psilocybin for treatment-resistant depression.

For people who have tried treatment after treatment and still feel disconnected from life, this research offers real reason for hope. The ability to feel pleasure, interest, and connection may not be lost for good. With careful preparation, skilled support, and continued research, psilocybin-assisted therapy may help people rediscover the parts of life worth enjoying.

Read the Study: Novick AM, Love TM, Johnson RL, et al. Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: a randomized controlled pilot trial. Journal of Affective Disorders. 2026. https://doi.org/10.1016/j.jad.2026.122676

Complimentary Consultation

Speak with a member of our clinical team to discuss your symptoms, goals, and whether a comprehensive evaluation is the right next step. This brief, no-obligation consult is designed to provide clarity and direction.

FREE Consult